Inclusion criteria included:
1. patients with a plasma level HIV RNA of less than 200 HIV-1 RNA
copies/ml or a decrease in plasma viral load of more than 1 log10
2. patients with immunologic failure if CD4 count decreased to
pre-therapy baseline (or below) or decreased by 50% from peak during
treatment (if known) or CD4 count remained below 100 cells/mm3 6 months
after ART initiation